(19)
(11) EP 4 511 004 A1

(12)

(43) Date of publication:
26.02.2025 Bulletin 2025/09

(21) Application number: 23725446.1

(22) Date of filing: 19.04.2023
(51) International Patent Classification (IPC): 
A61K 9/16(2006.01)
A61P 11/00(2006.01)
A61K 38/00(2006.01)
(52) Cooperative Patent Classification (CPC):
A61K 9/0075; A61P 11/00; A61K 9/1694; A61K 38/2006
(86) International application number:
PCT/IT2023/050105
(87) International publication number:
WO 2023/203586 (26.10.2023 Gazette 2023/43)
(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA
Designated Validation States:
KH MA MD TN

(30) Priority: 21.04.2022 IT 202200007844

(71) Applicants:
  • Università degli Studi di Perugia
    06123 Perugia (IT)
  • Fondazione Per La Ricerca Sulla Fibrosi Cistica - Onlus
    37126 Verona (IT)

(72) Inventors:
  • GIOVAGNOLI, Stefano
    06123 Perugia (PG) (IT)
  • PARIANO, Marilena
    06123 Perugia (PG) (IT)
  • PUCCETTI, Matteo
    06123 Perugia (PG) (IT)
  • RICCI, Maurizio
    06123 Perugia (PG) (IT)

(74) Representative: Gitto, Serena et al
Barzanò & Zanardo S.p.A. Via Piemonte, 26
00187 Roma
00187 Roma (IT)

   


(54) INHALABLE PHARMACEUTICAL COMPOSITION COMPRISING THE PROTEIN ANAKINRA FOR THE TREATMENT OF INFLAMMATION IN CYSTIC FIBROSIS